Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enVVeno MedicalNVNO +1.24%26 EV-to-EBITDA is 0.82 as of Aug. 16, 2026. GuruFocus rates NVNO with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 513 Medical Devices & Instruments companies, enVVeno Medical ranks better than 97.47% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, enVVeno Medical's enterprise value is $-13.48 Mil.
enVVeno Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-16.36 Mil. Therefore, enVVeno Medical's EV-to-EBITDA for today is 0.82.
The historical rank and industry rank for enVVeno Medical's EV-to-EBITDA or its related term are showing as below:
NVNO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -12.4 Med: -0.57 Max: 0.82
Current: 0.82
During the past 11 years, the highest EV-to-EBITDA of enVVeno Medical was 0.82. The lowest was -12.40. And the median was -0.57.
NVNO's EV-to-EBITDA is ranked better than 97.47% of 513
companies
in the Medical Devices & Instruments industry
Industry Median: 14.95
vs NVNO: 0.82
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
enVVeno Medical (NAS:NVNO) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
enVVeno Medical's PE Ratio (TTM) for today is calculated as:
enVVeno Medical's share price for today is $10.99.
enVVeno Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for enVVeno Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, enVVeno Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enVVeno Medical EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, enVVeno Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where enVVeno Medical's EV-to-EBITDA falls into.
enVVeno Medical's current Enterprise Value is $-13.48 Mil.
enVVeno Medical's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enVVeno Medical (NVNO) has a EV-to-EBITDA of 0.82 as of Aug. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on enVVeno Medical. According to the industry distribution chart, enVVeno Medical ranks #13 out of 513 companies in the Medical Devices & Instruments industry, placing it in the top 2.5%.
Is enVVeno Medical's EV-to-EBITDA too high?
enVVeno Medical's current EV-to-EBITDA is 0.82. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.95. enVVeno Medical's value of 0.82 is 94.5% below this industry median. Based on the distribution chart, enVVeno Medical ranks #13 out of 513 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, enVVeno Medical has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does enVVeno Medical's EV-to-EBITDA compare to CODX and HSCS?
According to the Medical Devices & Instruments industry distribution chart, enVVeno Medical ranks #13 out of 513 companies for EV-to-EBITDA. This places enVVeno Medical in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.95. enVVeno Medical's value of 0.82 is 94.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.95, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. enVVeno Medical's current EV-to-EBITDA of 0.82 is 94.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on enVVeno Medical. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. enVVeno Medical's current EV-to-EBITDA is 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enVVeno Medical stock overvalued right now?
enVVeno Medical (NVNO) has a current EV-to-EBITDA of 0.82. The current EV-to-EBITDA is 0.82 and 94.5% below the Medical Devices & Instruments industry median of 14.95. enVVeno Medical's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For enVVeno Medical (NVNO), the current EV-to-EBITDA is 0.82 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
26GF Score
Get the complete analysis for NVNO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVNO has been successfully added to your 
